• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
RCE
Click for more information
8.14% 46.5¢

RECCE PHARMACEUTICALS LTD - Charts / Financials

Market Cap $118.1M  ! watchlist Created with Sketch. Add to my watchlist

Recce Pharmaceuticals Ltd is an Australia-based company engaged in the development and... Recce Pharmaceuticals Ltd is an Australia-based company engaged in the development and commercialization of a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. The Company's anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses. All RECCE compounds are water soluble at all pH levels in their liquid form.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 15.48pm 03/12/2024 (20 minute delay) ?
Day
Open 43.0¢   Day High 46.5¢   Day Low 43.0¢
Daily Volume 121705
Bids   Sellers
Number Price Volume   Number Price Volume
2 45.0¢ 33067   1 47.0¢ 20000

Directors & Senior Management

Mr. James Hamilton Bray Graham Chief Executive Officer, Managing Director, Executive Director
Mr. Justin Reynolds Chief Financial Officer
Ms. Michele Keryn Dilizia Chief Scientific Officer, Executive Director
Dr. Philip Sutton Vice President of Translational Sciences
Dr. Justin Ward Executive Director and Principal Quality Chemist
Mr. Daniel Astudillo Head of Marketing
Mr. Thomas Jarrett Operations Manager
Ms. Maggie Niewidok Company Secretary
Dr. John Prendergast Independent Non- Executive Chairman of the Board
Mr. Alistair McKeough Non-Executive Director
Dr. Alan William Dunton Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
46.5¢ 		Change
0.035(8.14%) 		Mkt cap ! $118.1M
Open High Low Value Volume
43.0¢ 46.5¢ 43.0¢ $55.52K 121.7K

Buyers (Bids)

No. Vol. Price($)
2 33067 45.0¢
 

Sellers (Offers)

Price($) Vol. No.
47.0¢ 20000 1
View Market Depth
Last trade - 15.48pm 03/12/2024 (20 minute delay) ?
Last
46.5¢ 		  Change
0.035 ( 5.68 %)
Open High Low Volume
45.0¢ 46.5¢ 45.0¢ 48153
Last updated 15.48pm 03/12/2024 ?

Top Stories

Breaking news: New opportunities for investors & companies - HotCopper opens to capital raising!

Companies can now raise capital through HotCopper! It’s a development allowing a highly cost-effective service to ASX-listed companies, while opening new investment opportunities to investors.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.